Lanreotide

Lanreotide is a synthetic octapeptide analog of somatostatin with preferential binding to somatostatin receptor subtypes 2 and 5 (SSTR2 and SSTR5), similar to octreotide. Developed by Ipsen, lanreotide is formulated as a supersaturated solution that forms a depot upon deep subcutaneous injection, providing sustained drug release over 4 weeks. This unique Autogel/Depot formulation allows self-administration by patients or caregivers after appropriate training, a significant practical advantage over octreotide LAR, which requires intramuscular injection by a healthcare professional.

Lanreotide inhibits the secretion of growth hormone, thyroid-stimulating hormone, and various gastrointestinal and pancreatic hormones. In acromegaly, it reduces GH and IGF-1 levels in a substantial proportion of patients and may reduce pituitary tumor volume. Clinical trials have shown comparable efficacy to octreotide LAR in controlling acromegaly, and the choice between the two drugs often comes down to patient preference regarding administration and practical considerations.

The CLARINET trial was a landmark study that established lanreotide's antiproliferative effect in non-functioning gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This randomized, double-blind, placebo-controlled trial demonstrated that lanreotide Autogel significantly prolonged progression-free survival in patients with advanced, well-differentiated GEP-NETs, with a 53% reduction in the risk of disease progression or death. This trial expanded the indication for lanreotide beyond symptomatic control to include tumor growth inhibition.

Lanreotide has also been investigated for the treatment of thyroid-stimulating hormone-secreting pituitary adenomas and for polycystic kidney and liver disease, where early studies suggested it may slow cyst growth by inhibiting cAMP-mediated fluid secretion.